Insulin Secretagogue Drugs
    1.
    发明申请
    Insulin Secretagogue Drugs 审中-公开
    胰岛素促分泌药物

    公开(公告)号:US20080207710A1

    公开(公告)日:2008-08-28

    申请号:US11630112

    申请日:2004-12-14

    IPC分类号: A61K31/426

    CPC分类号: C07D277/26 A61K31/426

    摘要: Demanded is an insulin secretagogue that alleviates side effects, such as acceleration of obesity and cells so as not to be detrimental to insulin secretion β capability. The invention provides an insulin secretagogue agent not only dependent on glucose but also responsive to elevated blood sugar levels, comprising an effective amount of a substance having the activity of PPAR δ activation. This insulin secretagogue simultaneously exerts anti-obesity activity, serum cholesterol reducing activity useful for the treatment and prevention of arteriosclerosis, etc. and insulin resistance ameliorating activity.

    摘要翻译: 需要的是胰岛素促分泌素,其减轻副作用,例如加速肥胖和细胞,以免对胰岛素分泌β能力不利。 本发明提供了不仅依赖于葡萄糖而且还对血糖水平升高有反应的胰岛素促分泌剂,其包含有效量的具有PPARδ活化活性的物质。 该胰岛素促分泌剂同时施用抗肥胖活性,可用于治疗和预防动脉硬化等的血清胆固醇降低活性,以及​​胰岛素抵抗改善活性。